<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03011398</url>
  </required_header>
  <id_info>
    <org_study_id>RSI2015-REG01</org_study_id>
    <nct_id>NCT03011398</nct_id>
  </id_info>
  <brief_title>A Clinical Registry of Orthobiologics Procedures</brief_title>
  <official_title>Interventional Orthopedics Foundation Patient Registry Database-A Clinical Registry of Orthobiologics Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenexx, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenexx, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Registry study is to observe the improvement in subject-reported clinical&#xD;
      outcomes for percutaneous orthopedic procedures for treatment of musculoskeletal disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Registry was designed to assure that the benefits and knowledge gained by studying&#xD;
      clinical outcomes associated with the use of percutaneous orthopedic procedures outweigh the&#xD;
      potential risks to the patients. The primary objective of this Registry is to observe the&#xD;
      improvements in subject-reported clinical outcomes for these procedures used to treat&#xD;
      musculoskeletal disorders. Secondary objectives include evaluating post-treatment&#xD;
      complication, adverse events, re-injections, and surgical intervention. Patients receiving&#xD;
      percutaneous orthopedic treatments are asked to enroll before receiving treatment and&#xD;
      complete a set of baseline questionnaires regarding pain and functionality of the area of the&#xD;
      body being treated (i.e. knee, shoulder, spine, etc). Follow-up outcomes are collected at 1&#xD;
      month, 3 months, 6 months, 12 months, 18 months, and annually 2-20 years post-injection.&#xD;
      Subjects are withdrawn from the Registry prematurely if a surgical operation occurs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2036</completion_date>
  <primary_completion_date type="Anticipated">February 2036</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Change in Percent Improvement</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Mean improvement score, where -100=100% worse from baseline and 100=100% better or improved from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Mean numeric pain score, where 0=no pain and 10=worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee form</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Mean IKDC score, where 0=lowest level of knee function and 100=highest level of knee function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Function Scale</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Means LEFS score, where 0=very low function of the lower extremity and 80=very high function of the lower extremity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disabilities of the Arm, Shoulder and Hand form</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Mean DASH score, where 0=no disability of the upper extremity and 100=most severe disability of the upper extremity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Hip Score</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Mean OHS score, where 42-48=excellent, 34-41=good, 27-33=fair, 0-26=poor for hip pain and function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Rating Index</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Mean FRI score, where 0=no disability in function of the neck and back and 100=severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Description of any medical complication related to receiving a treatment procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Description of adverse events occurring after treatment procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Re-injections to treated area</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>number of additional injections to treated area such as platelet rich plasma or stem cell treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Surgical Interventions to treated area</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment</time_frame>
    <description>Number of surgical interventions to treated area after receiving treatment procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Orthopedic Disorder</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Orthobiologic Procedures</intervention_name>
    <description>To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients treated with orthobiologics procedures&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidates must meet ALL of the following:&#xD;
&#xD;
               1. Voluntary signature of the IRB approved Informed Consents,&#xD;
&#xD;
               2. Treated with a Regenexx procedure&#xD;
&#xD;
               3. Have a musculoskeletal condition appropriate for the procedure such as&#xD;
                  osteoarthritis or internal joint derangement; ligament or tendon injury;&#xD;
                  intervertebral disc degeneration; protrusion, extrusion, or annular tear; muscle&#xD;
                  tear&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Centeno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regenerative Sciences, LLC and Centeno-Schultz Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catalyst Pain Solutions</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthlink Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthlink Center</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthlink Center</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <zip>94903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Orthopedic Institute</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Orthopedic Institute-Van Nuys</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centeno-Schultz Clinic</name>
      <address>
        <city>Broomfield</city>
        <state>Colorado</state>
        <zip>80021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regenexx</name>
      <address>
        <city>Broomfield</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New reGeneration Orthopedics</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Arthritis</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Stem Cell Resource</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor View Medical</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodyworks Musculoskeletal Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Care-LA</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stem Cell ARTS-MD</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RejuvMedical</name>
      <address>
        <city>Waite Park</city>
        <state>Minnesota</state>
        <zip>56387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Sports Medicine</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <zip>07927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Stem Cell Solutions</name>
      <address>
        <city>Oakhurst</city>
        <state>New Jersey</state>
        <zip>07755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Center of New Jersey</name>
      <address>
        <city>Wayne</city>
        <state>New Jersey</state>
        <zip>07470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Orthopaedics</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RegenOrthoSport</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Pain Management</name>
      <address>
        <city>Hood River</city>
        <state>Oregon</state>
        <zip>97031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation and Pain Specialists</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Sports Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Pennsylvania</state>
        <zip>19064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RegenOrthoSport</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Pain Solutions</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Regenerative Medicine</name>
      <address>
        <city>Winooski</city>
        <state>Vermont</state>
        <zip>05404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stem Cell ARTS-VA</name>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <zip>22102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Specialist Sports Medicine</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RegenOrthoSport</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2010 Mar;5(1):81-93. doi: 10.2174/157488810790442796.</citation>
    <PMID>19951252</PMID>
  </reference>
  <reference>
    <citation>Centeno CJ, Schultz JR, Cheever M, Freeman M, Faulkner S, Robinson B, Hanson R. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2011 Dec;6(4):368-78. doi: 10.2174/157488811797904371.</citation>
    <PMID>22023622</PMID>
  </reference>
  <reference>
    <citation>Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006 Sep;91(9):1293-4.</citation>
    <PMID>16956842</PMID>
  </reference>
  <reference>
    <citation>Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010 Jun;38(6):1110-6. doi: 10.1177/0363546509359067. Epub 2010 Apr 14.</citation>
    <PMID>20392971</PMID>
  </reference>
  <reference>
    <citation>Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, Kuroda R, Kurosaka M, Yoshiya S, Hattori K, Ohgushi H. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. 2011 Feb;5(2):146-50. doi: 10.1002/term.299.</citation>
    <PMID>20603892</PMID>
  </reference>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>December 29, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>January 25, 2022</last_update_submitted>
  <last_update_submitted_qc>January 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03011398
org study id: RSI2015-REG01
nct id: NCT03011398
lead sponsor: 
has dmc: No
The purpose of the Registry study is to observe the improvement in subject-reported clinical
      outcomes for percutaneous orthopedic procedures for treatment of musculoskeletal disorders.
This Registry was designed to assure that the benefits and knowledge gained by studying
      clinical outcomes associated with the use of percutaneous orthopedic procedures outweigh the
      potential risks to the patients. The primary objective of this Registry is to observe the
      improvements in subject-reported clinical outcomes for these procedures used to treat
      musculoskeletal disorders. Secondary objectives include evaluating post-treatment
      complication, adverse events, re-injections, and surgical intervention. Patients receiving
      percutaneous orthopedic treatments are asked to enroll before receiving treatment and
      complete a set of baseline questionnaires regarding pain and functionality of the area of the
      body being treated (i.e. knee, shoulder, spine, etc). Follow-up outcomes are collected at 1
      month, 3 months, 6 months, 12 months, 18 months, and annually 2-20 years post-injection.
      Subjects are withdrawn from the Registry prematurely if a surgical operation occurs.
observational model: Case-Control
time perspective: Prospective
measure: Change in Percent Improvement
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Mean improvement score, where -100=100% worse from baseline and 100=100% better or improved from baseline
measure: Pain Scale
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Mean numeric pain score, where 0=no pain and 10=worst possible pain.
measure: International Knee Documentation Committee form
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Mean IKDC score, where 0=lowest level of knee function and 100=highest level of knee function.
measure: Lower Extremity Function Scale
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Means LEFS score, where 0=very low function of the lower extremity and 80=very high function of the lower extremity
measure: Disabilities of the Arm, Shoulder and Hand form
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Mean DASH score, where 0=no disability of the upper extremity and 100=most severe disability of the upper extremity.
measure: Oxford Hip Score
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Mean OHS score, where 42-48=excellent, 34-41=good, 27-33=fair, 0-26=poor for hip pain and function.
measure: Functional Rating Index
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Mean FRI score, where 0=no disability in function of the neck and back and 100=severe disability.
measure: Complications
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Description of any medical complication related to receiving a treatment procedure
measure: Adverse Events
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Description of adverse events occurring after treatment procedure
measure: Number of Re-injections to treated area
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: number of additional injections to treated area such as platelet rich plasma or stem cell treatment
measure: Number of Surgical Interventions to treated area
time frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment
description: Number of surgical interventions to treated area after receiving treatment procedure
intervention type: Procedure
intervention name: Orthobiologic Procedures
description: To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: N/A
maximum age: N/A
healthy volunteers: No
last name: Christopher Centeno, MD
role: Principal Investigator
affiliation: Regenerative Sciences, LLC and Centeno-Schultz Clinic
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: India
country: United States
citation: Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2010 Mar;5(1):81-93. doi: 10.2174/157488810790442796.
PMID: 19951252
citation: Centeno CJ, Schultz JR, Cheever M, Freeman M, Faulkner S, Robinson B, Hanson R. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2011 Dec;6(4):368-78. doi: 10.2174/157488811797904371.
PMID: 22023622
citation: Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006 Sep;91(9):1293-4.
PMID: 16956842
citation: Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010 Jun;38(6):1110-6. doi: 10.1177/0363546509359067. Epub 2010 Apr 14.
PMID: 20392971
citation: Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, Kuroda R, Kurosaka M, Yoshiya S, Hattori K, Ohgushi H. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. 2011 Feb;5(2):146-50. doi: 10.1002/term.299.
PMID: 20603892
responsible party type: Sponsor
mesh term: Musculoskeletal Diseases
sharing ipd: No